References

Filters: Author is Wyles, David  [Clear All Filters]
W
Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir [Epub ahead of print]. Antiviral Therapy. 2017;.
Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, et al.. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2017;65(1):6-12.
Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial: Viral Hepatitis. Hepatology. 2018;67(2):514 - 523.
Top